Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection

被引:12
作者
Shoemaker, NE
Rosing, H
Jansen, S
Schöffski, P
Rizzo, J
Schellens, JHM
Beijnen, JH
机构
[1] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands
[2] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[3] Hannover Med Sch, Dept Hematol & Oncol, Hannover, Germany
[4] Canc Therapy & Res Ctr S Texas, Inst Drug Dev, Clin Bioanal Lab, San Antonio, TX 78229 USA
[5] Univ Utrecht, Fac Pharm, Div Drug Toxicol, Utrecht, Netherlands
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2002年 / 775卷 / 02期
关键词
9-nitrocamptothecin; 9-aminocamptothecin;
D O I
10.1016/S1570-0232(02)00294-5
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
A high-performance liquid chromatography assay is described for the determination of the investigational anti-cancer drug 9-nitrocamptothecin (9-NC) and its metabolite 9-aminocamptothecin (9-AC) as the total of their lactone and carboxylate forms. The sample pre-treatment consisted of a deproteinisation step and a quantitative acid-catalyzed conversion of all 9-NC and 9-AC into their lactone forms and a subsequent solid-phase extraction. Redissolved extracts were analyzed on a Prodigy analytical column, using a mixture of methanol-phosphate buffer (pH 2.5). Detection was concomitantly performed with UV for 9-NC and fluorimetrically for 9-AC. The lower limit of quantifications were 10 ng/ml and 2.5 ng/ml for the determination of 9-NC and 9-AC, respectively, using 500 mul of plasma. The presented method was successfully applied to a clinical pharmacokinetic study. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:231 / 237
页数:7
相关论文
共 17 条
[1]
Bernacki RJ, 2000, ANN NY ACAD SCI, V922, P293
[2]
Clinical pharmacokinetics of irinotecan [J].
Chabot, GG .
CLINICAL PHARMACOKINETICS, 1997, 33 (04) :245-259
[3]
Han ZY, 2001, ANTICANCER RES, V21, P1823
[4]
HINZ HR, 1994, CANCER RES, V54, P3096
[5]
Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection [J].
Loos, WJ ;
Sparreboom, A ;
Verweij, J ;
Nooter, K ;
Stoter, G ;
Schellens, JHM .
JOURNAL OF CHROMATOGRAPHY B, 1997, 694 (02) :435-441
[6]
Camptothecins: a review of their development and schedules of administration [J].
O'Leary, J ;
Muggia, FM .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (10) :1500-1508
[7]
PANTAZIS P, 1994, EUR J HAEMATOL, V53, P246
[8]
PANTAZIS P, 1994, CANCER RES, V54, P771
[9]
PHARMACOLOGICAL CORRELATION BETWEEN TOTAL DRUG CONCENTRATION AND LACTONES OF CPT-11 AND SN-38 IN PATIENTS TREATED WITH CPT-11 [J].
SASAKI, Y ;
YOSHIDA, Y ;
SUDOH, K ;
HAKUSUI, H ;
FUJII, H ;
OHTSU, T ;
WAKITA, H ;
IGARASHI, T ;
ITOH, K .
JAPANESE JOURNAL OF CANCER RESEARCH, 1995, 86 (01) :111-116
[10]
SCHOFFSKI P, 2001, P AM SOC CLIN ONCOL, V20, P405